|
|
|
| home > ebr > Autumn 2019 |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review |
|
|
|
|
|
 |
| |
|
|
|
|
|
Stem Cell Therapy
Recombinant Human Albumin
Cryopreservation and stem cell therapies are facing major changes and
advancements, Dr Phil Morton and Dr Daniel Shelly at Albumedix discuss
how albumin is useful across the cell therapy value chain.
|
|
|
|
Live Cell Transport
The Rising Star
The way in which we transport existing cell shipments is continuously being optimised, and Dr Corné Swart at Cellbox Solutions looks into these new devices that allow cells to survive compared to traditional methods.
|
|
|
|
|
|
Orphan Drugs and Rare Diseases
Patient Voices in the Industry
When considering the development of orphan drugs, the patients that suffer from the diseases and help process drug development in clinical trials also have to be considered, write William C Maier and Kelly Franchetti at ICON.
|
|
|
|
|
|
Biopharmaceutical Applications
The Advantages of Long-Read Sequencing
Jonas Korlach at Pacific Biosciences discusses the improvements in long-read sequencing technology, and the applications it may have in the discovery of new drugs.
|
|
|
|
Advances in Oncology
Advancing Liquid Biopsies
Mark Li at Resolution Bioscience examines why liquid biopsies are now becoming more commonly used compared to tissue biopsies.
|
|
|
|
|
|
The Potential of Medical Cannabis
Budding Opportunities for Pharma
Shifting attitudes towards cannabis-based medicines are making them more appealing to drug developers, which will in turn help patients who need these drugs, writes Callum McGuinn at Mewburn Ellis.
|
|
|
|
The Future of Clinical Research on Medical Cannabis
Trial by Fire
Dr Mark A Ware at Canopy Growth Corporation describes the changes in drug policy in recent times surrounding cannabis-based drugs, and the advantages they may have in treating patients.
|
|
|
|
|
In Brief
Vax Populi
EBR’s Industry Advisor, Emile Bellott, discusses the health achievement of vaccinations against infectious diseases in the post-industrial era, and how immunisation is essential to continue saving millions of lives every year.
|
|
|
|
|
Anti-Idiotypic Antibodies
Robust Method Development for Biologics and Biosimilars
Amanda Turner at Bio-Rad Laboratories examines the factors that enable the demand for biological medicines to evolve and expand, such as the introduction of lower-cost biosimilars, or the ongoing identification of new drug targets.
|
|
|
|
Preclinical Oncological Research
PET Technology and Tumour Progression
Dr Todd Sasser at Bruker BioSpin writes on how, with the advancements of PET scanning, oncologists are now better able to understand the development of cancers and tumours by better highlighting their morphology and other biomarkers.
|
|
|
|
Accelerating Process Development
Simply Good Monitoring
Paul Kroll and Alexandra Hofer at Securecell AG articulate how digitisation can accelerate process development in relation to the analysis of liquid samples.
|
|
|
|
High-Productivity Membrane Chromatography
The Next-Generation Purification of Monoclonal Antibodies
Gary Skarja at Merck examines the key developments in mAb manufacturing, including the benefits that address productivity and cost challenges in a singleuse format.
|
|
|
|
Challenges in Cellular, Tissue, and Gene Therapy Products
Drug Development Decisions
Cost control in drug development is always at the forefront of manufacturer’s minds, and Zeb Younes and Zaklina Buljovcic at PharmaLex examine how automation and decentralising the manufacturing process can help achieve this goal in the long run.
|
|
|
|
Developments in Artificial Intelligence
Focusing on Target Safety
Although in its infancy, Ruth Roberts at ApconiX describes how artificial intelligence can help reduce the cost and the amount of product failures in regard to drug development and creation.
|
|
|
|
Standardising Conditions for Extractables Testing
Exhaustive Extraction
Simone Carrara and Michele Vasso at Eurofins illustrate the importance of extractables and leachables to ensure drug efficacy, and that the product remains in optimal condition to interact with the patient.
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
KITE’S CAR T-CELL THERAPY TECARTUS® (BREXUCABTAGENE AUTOLEUCEL) GRANTED EUROPEAN MARKETING AUTHORISATION FOR THE TREATMENT OF RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKAEMIA (r/r ALL)
Stockley Park, UK – 7 September 2022 – Kite, a Gilead Company,
today announced that the European Commission (EC) has approved its CAR
T-cell therapy Tecartus® (brexucabtagene autoleucel) for the treatment
of adult patients 26 years of age and above with relapsed or refractory
(r/r) B-cell precursor acute lymphoblastic leukaemia (ALL).
More info >> |
|
 |
White Papers |
 |
|
By Your Side for a Healthier World
West Pharmaceutical Services, Inc.
Every day, injectable drugs are administered to improve the lives of millions of patients around the world. And every day, West is working by your side to design and manufacture drug packaging and delivery systems that will bring our customers’ drugs from concept to the patient more efficiently, reliably and safely. West understands our customers’ challenges and helps with solutions every step of the way, with cutting-edge production technologies, an unmatched expertise in global regulatory compliance, and an ever-growing knowledge base of pharmaceutical drug product testing, development, packaging and delivery. Whether focused on one piece of the process or an end-to-end solution, West is by your side for a healthier world.
More info >> |
|
|
